The HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market is expected to grow at a CAGR of 9.94% to reach USD 11066.53 million by 2028. The high cost of HER2 inhibitors poses a significant challenge for patient adoption, potentially impacting market sales negatively. Pharmaceutical companies, such as Roche, are addressing this issue by implementing patient assistance programs. For instance, Roche's Herceptin Access Solutions and PERJETA Financial Assistance provide financial assistance for Herceptin and other oncology drugs. The Genentech BioOncology Co-pay Card Program enables patients to pay as little as USD5 for their prescribed Genentech BioOncology products, including Herceptin, with an annual benefit limit of USD25,000 per product. These initiatives aim to alleviate the financial burden on patients, thereby increasing the accessibility and utilization of these essential treatments.
North America dominates the regional market because of The HER2 inhibitors market in the US is experiencing robust growth due to the increasing demand for advanced treatment options for various cancers caused by the overexpression of the HER2 protein. Notably, HER2-positive carcinomas, such as metastatic gastric or gastroesophageal junction adenocarcinoma, NSCLC, and breast cancer, are primary drivers of market expansion. For instance, approximately 200,000 breast cancer cases are diagnosed annually in the US, with HER2-positive breast cancer accounting for a substantial proportion. Moreover, the CDC reports that over 28.5 million invasive cancer cases have been diagnosed since 2000, highlighting the significant need for specialized therapies. This high prevalence of cancer necessitates the development and utilization of effective HER2 inhibitors to address this unmet medical need.
There are various factors that drive the HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market market which are as following: The Human Epidermal Growth Factor Receptor 2 (HER2) plays a crucial role in regulating cell growth, survival, and differentiation through various signal transduction pathways. However, its overexpression can lead to the development of several cancers, such as breast and gastric cancer. According to the National Institutes of Health (NIH), approximately 15-30% of breast cancer and 10-30% of gastric cancer cases exhibit HER2 amplification or overexpression. These cancer cells, referred to as HER2-positive cells, proliferate at an accelerated rate due to the excess HER2 expression. Consequently, the prevalence of HER2-positive breast and gastric cancers continues to rise, necessitating the development of effective therapeutic interventions in the form of HER2 inhibitors.
Be the first one to get the industry updates. Request for a sample report
HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market Segmentation
The market witnesses several challenges, which are as follows The exorbitant cost of Human Epidermal Growth Factor Receptor 2 (HER2) inhibitors, such as trastuzumab and pertuzumab, poses a substantial challenge for the market, negatively impacting both individuals and healthcare systems. These medications, essential for treating HER2-positive breast and gastric malignancies, carry significant price tags. For example, trastuzumab, a widely-used HER2 inhibitor, can cost an annual sum exceeding USD70,000 for a US patient. Pertuzumab adds additional expense to the treatment regimen, potentially amounting to thousands of dollars more. Even patients with insurance coverage often face financial hardships due to these costs, which may compel them to discontinue therapy.
Stay ahead of your competitors. Download the Free PDF report
Some of the key companies that have been profiled in the report include:
The HER2 inhibitors market, a segment of the expansive global pharmaceuticals industry, is a key focus area for Technavio in the healthcare sector. The pharmaceuticals market encompasses entities involved in R&D or manufacturing of various drug classes, including generic and non-generic medicines, as well as veterinary drugs. The healthcare industry's overall market size is determined by Technavio based on the consolidated revenue generated by providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Factors driving the growth of the global pharmaceuticals market include the increasing elderly population, with the number of individuals aged 60 and above projected to rise significantly. - The HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market is experiencing significant growth, fueled by the High prevalence of breast cancer and gastric cancer. Businesses are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
The HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market has witnessed significant growth in recent years due to the increasing prevalence of HER2-positive cancers, particularly in Breast and Ovarian Cancer. According to quantitative data from market research reports, the global HER2 Inhibitors Market is projected to reach a value of USD35.3 billion by 2027, growing at a CAGR of 11.5% during the forecast period. Pyrotinib, Tucatinib, Neratinib, Lapatinib, and Herceptin are some of the notable HER2 Inhibitors used in the treatment of HER2-positive cancers. Biomarker testing is crucial in identifying patients who will benefit from these precision medicines. Patient advocacy groups and precision oncology adoption are driving the use of alternative treatment options like Herceptin biosimilars and monoclonal antibodies. Biotechnological advances have led to the development of combination therapy and monotherapy using HER2 receptor proteins and Anti-HER2 drugs. Monoclonal antibodies like Herceptin and Tyrosine kinase inhibitors like Lapatinib, Neratinib, and Tucatinib are the two main classes of HER2 Inhibitors. Gastric and Breast cancers are the primary indications for HER2 Inhibitors. The healthcare industry's focus on improving patient outcomes and reducing costs is expected to further fuel market growth.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
